Indaptus director granted options for 25,000 shares

Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock.

Rhea-AI Filing Summary

Indaptus Therapeutics director David Natan received a new stock option grant covering 25,000 shares of common stock. The options have an exercise price of $2.69 per share and were granted on January 7, 2026 under the company’s non-employee director compensation program. The award vests over three years in equal quarterly installments starting from the grant date, as long as Natan continues to serve on the board through each vesting date. Following this grant, he beneficially holds 25,000 stock options directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider NATAN DAVID

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Buy Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Option to Buy Common Stock — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indaptus Therapeutics (INDP) report for David Natan?

The company reported that director David Natan received a grant of stock options to purchase 25,000 shares of common stock on January 7, 2026.

What is the exercise price of David Natan’s new Indaptus (INDP) stock options?

The options granted to David Natan have an exercise price of $2.69 per share for Indaptus Therapeutics common stock.

How do David Natan’s Indaptus (INDP) director stock options vest?

The stock options vest over three years in equal quarterly installments starting from the grant date, contingent on his continued service on the board through each vesting date.

How many Indaptus (INDP) options does David Natan hold after this transaction?

After this grant, David Natan beneficially owns 25,000 stock options to purchase Indaptus Therapeutics common stock, held directly.

Is David Natan’s option grant part of an Indaptus (INDP) director compensation program?

Yes. The filing states that the options were granted pursuant to Indaptus Therapeutics’ non-employee director compensation program.

Does David Natan pay anything for these Indaptus (INDP) options at grant?

The filing shows a per-derivative price of $0 at grant, with the right to buy shares later at the $2.69 exercise price if the options are exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 09:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NATAN DAVID

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC.

3 COLUMBUS CIRCLE, 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Buy Common Stock	$2.69	01/07/2026		A		25,000		(1)	01/07/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.

	/s/ David Natan	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.